AISIN SEIKI CO/ADR (OTCMKTS:ASEKY) Upgraded to Hold at ValuEngine

Share on StockTwits

ValuEngine upgraded shares of AISIN SEIKI CO/ADR (OTCMKTS:ASEKY) from a sell rating to a hold rating in a research note published on Thursday morning, ValuEngine reports.

Separately, Zacks Investment Research lowered AISIN SEIKI CO/ADR from a hold rating to a strong sell rating in a research report on Wednesday, June 5th.

Shares of ASEKY opened at $33.95 on Thursday. The firm has a market capitalization of $9.15 billion, a price-to-earnings ratio of 9.20 and a beta of 1.47. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.12 and a current ratio of 1.45. The business’s fifty day moving average price is $30.01 and its two-hundred day moving average price is $34.54. AISIN SEIKI CO/ADR has a 52 week low of $27.73 and a 52 week high of $48.28.

AISIN SEIKI CO/ADR Company Profile

Aisin Seiki Co, Ltd. manufactures and sells automotive parts, lifestyle and energy related products, and wellness related products worldwide. It offers powertrain related products, such as automatic, manual, and hybrid transmission products; and CVT, engine, and other products. The company also provides chassis and vehicle safety systems comprising parking assist systems, driver monitoring systems, disc brakes, brake assemblies, electric parking brakes, brake master cylinder with brake assistance, electronically controlled brake systems, ABS and ESC modulators, brake calipers, power tilt and telescopic steering columns, air suspension systems, and active rear steering systems.

Further Reading: Overbought

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for AISIN SEIKI CO/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AISIN SEIKI CO/ADR and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

-$0.54 Earnings Per Share Expected for Epizyme Inc  This Quarter
-$0.54 Earnings Per Share Expected for Epizyme Inc This Quarter
Peel Hunt Reaffirms Buy Rating for IQE
Peel Hunt Reaffirms Buy Rating for IQE
APERAM/SH N Y REGISTRY SH  Downgraded to Sell at Zacks Investment Research
APERAM/SH N Y REGISTRY SH Downgraded to Sell at Zacks Investment Research
Fiserv  Coverage Initiated by Analysts at UBS Group
Fiserv Coverage Initiated by Analysts at UBS Group
Adverum Biotechnologies  Downgraded by Zacks Investment Research
Adverum Biotechnologies Downgraded by Zacks Investment Research
Pantheon Resources  Shares Cross Below 200-Day Moving Average of $19.70
Pantheon Resources Shares Cross Below 200-Day Moving Average of $19.70


© 2006-2019 Ticker Report